Mon, February 16, 2009
Sun, February 15, 2009
Sat, February 14, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009

Active Biotech Active Biotech A Byear End Report January- December 2008

  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. ch-a-byear-end-report-january-december-2008.html
  Print publication without navigation Published in Science and Technology on , Last Modified on 2009-02-12 03:22:07 by Market Wire
          🞛 This publication is a summary or evaluation of another publication

LUND, SWEDEN--(Marketwire - February 12, 2009) -


 * Laquinimod -- Phase III Allegro study fully enrolled * 57-57 -- Phase II/III program only to be initiated in cooperation with partner * RhuDex™ -- additional preclinical trials being performed * ANYARA -- presentation of data in combination with established tumor drug * TASQ -- Phase II study proceeding as planned * Net sales SEK 53.5 M (12.1) * Operating loss SEK 184.6 M (loss: 202.7) * Loss after tax SEK 181.6 M (loss: 207.7) * Loss per share for the year was SEK 3.66 (loss: 4.47) For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 

This report is also available at [ www.activebiotech.com ]

Active Biotech Year End Report Jan-Dec 2008 -- [ http://hugin.info/1002/R/1289660/290518.pdf ]

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.



Similar Science and Technology Publications